Table 2.

Primary clinical measures and outcomes by treatment conditions.

	Placebo (n=46)			NB (n=43)
	n	M	SD	n	M	SD
EDE Binge Eating
Pre-Treatment	46	15.85	10.26	43	15.51	12.25
Post-Treatment	44	5.39	9.56	38	6.42	10.61
Change	44	−10.86	10.91	38	−9.58	11.99
Weight (kg)
Pre-Treatment	46	98.00	19.24	43	103.03	24.63
Post-Treatment	43	96.57	19.03	36	99.75	24.25
Change	43	−0.23	4.02	36	−3.61	5.12
% Change	43	−0.10	4.24	36	−3.44	5.24
Weight (pounds)
Pre-Treatment	46	216.06	42.42	43	227.14	54.31
Post-Treatment	43	212.89	41.96	36	219.91	53.46
Change	43	−0.50	8.86	36	−7.97	11.28
% Change	43	−0.10	4.24	36	−3.44	5.24
BMI
Pre-Treatment	46	34.71	5.99	43	35.90	6.25
Post-treatment	43	34.26	5.65	36	34.64	6.36
Change	43	−0.10	1.49	36	−1.19	1.82

Note: Binge eating (frequency during previous 28 days) and percent weight loss were the

pre-specified co-primary outcomes.

EDE = Eating Disorder Examination Interview; BMI = body mass index; NB = naltrexone/bupropion;

N = number; M = mean; SD = standard deviation.